Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of […]

Evergold Announces $300,000 Ore Group Financing, Sharpened Focus on Golden Lion Project, Toodoggone District, Northern BC GlobeNewswire January 05, 2026 TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Evergold Corp. (TSX-V: EVER, WKN: A2PTHZ) (“Evergold” or the “Company“) is pleased to announce a strategic non-brokered private placement (the “Financing“) with principals associated with the Ore Group,

Orion Group Holdings Awarded $86.3 Million U.S. Army Corps of Engineers Project GlobeNewswire January 05, 2026 HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE:ORN) (“Orion” or the “Company”), a leading specialty construction company, today announced it was awarded an $86.3 million project with the U.S. Army Corps of Engineers (USACE). “We

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category GlobeNewswire January 05, 2026 Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash

Lantronix Previews Turnkey Drone Reference Platform to Accelerate Defense and Commercial UAV Development Lantronix introduces a fully integrated compute, sensing and flight control platform designed to significantly shorten OEM time to market, debuting at CES 2026 GlobeNewswire January 05, 2026 LAS VEGAS, Jan. 05, 2026 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader

Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines The paper describes Frontier's innovative dDRTC method, which enables a more rapid assessment of covalent binding efficiency GlobeNewswire January 05, 2026 BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a clinical-stage precision

Alta Equipment Group Announces Preferred Stock Dividend GlobeNewswire January 05, 2026 LIVONIA, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) — Alta Equipment Group Inc. (NYSE: ALTG) (“Alta” or “the Company”), a leading provider of premium material handling, construction and environmental processing equipment and related services, today announced that its Board of Directors approved the quarterly dividend

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 11:15 a.m. PT. The live

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 05, 2026 BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T.